Bilkul Online | Ahmedabad | 15 Sept 2025
Alembic Pharmaceuticals Limited has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its API-I and API-II facilities at Panelav. The inspection was conducted between May 26 and May 31, 2025.
Founded in 1907, Alembic is a vertically integrated, research-driven pharmaceutical company headquartered in India. The company manufactures and markets generic medicines globally, with its advanced research and manufacturing facilities approved by regulators in several developed markets, including the USFDA.
Alembic is also a leading player in branded generics in India, with a strong portfolio promoted through a field force of over 5,500 representatives. Its brands enjoy wide recognition among both doctors and patients.